Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20629023rdf:typepubmed:Citationlld:pubmed
pubmed-article:20629023lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C0033325lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C1512162lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C0684224lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C0004927lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C0677874lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C1578536lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C1511572lld:lifeskim
pubmed-article:20629023lifeskim:mentionsumls-concept:C2348205lld:lifeskim
pubmed-article:20629023pubmed:issue21lld:pubmed
pubmed-article:20629023pubmed:dateCreated2010-10-25lld:pubmed
pubmed-article:20629023pubmed:abstractTextPatients with newly diagnosed acute myeloid leukemia (AML) often have residual leukemia in the bone marrow 10 to 14 days after the start of induction therapy. Some cooperative groups administer a second cycle of similar induction therapy on Day 14 if there is residual leukemia. It is a common perception that the presence of residual leukemia at that point predicts a worse prognosis irrespective of the therapy received. The objective of this study was to determine whether patients who required a second cycle of induction (given on or about Day 14) to achieve complete remission (CR) had a worse prognosis than patients who achieved CR after only 1 cycle, because a worse prognosis may alter postremission therapy.lld:pubmed
pubmed-article:20629023pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20629023pubmed:languageenglld:pubmed
pubmed-article:20629023pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20629023pubmed:citationSubsetAIMlld:pubmed
pubmed-article:20629023pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20629023pubmed:statusMEDLINElld:pubmed
pubmed-article:20629023pubmed:monthNovlld:pubmed
pubmed-article:20629023pubmed:issn0008-543Xlld:pubmed
pubmed-article:20629023pubmed:authorpubmed-author:RoweJacob MJMlld:pubmed
pubmed-article:20629023pubmed:authorpubmed-author:LitzowMark...lld:pubmed
pubmed-article:20629023pubmed:authorpubmed-author:WiernikPeter...lld:pubmed
pubmed-article:20629023pubmed:authorpubmed-author:TallmanMartin...lld:pubmed
pubmed-article:20629023pubmed:authorpubmed-author:LazarusHillar...lld:pubmed
pubmed-article:20629023pubmed:authorpubmed-author:KimHaesook...lld:pubmed
pubmed-article:20629023pubmed:authorpubmed-author:CassilethPete...lld:pubmed
pubmed-article:20629023pubmed:copyrightInfoCopyright © 2010 American Cancer Society.lld:pubmed
pubmed-article:20629023pubmed:issnTypePrintlld:pubmed
pubmed-article:20629023pubmed:day1lld:pubmed
pubmed-article:20629023pubmed:volume116lld:pubmed
pubmed-article:20629023pubmed:ownerNLMlld:pubmed
pubmed-article:20629023pubmed:authorsCompleteYlld:pubmed
pubmed-article:20629023pubmed:pagination5012-21lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:meshHeadingpubmed-meshheading:20629023...lld:pubmed
pubmed-article:20629023pubmed:year2010lld:pubmed
pubmed-article:20629023pubmed:articleTitleAdult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.lld:pubmed
pubmed-article:20629023pubmed:affiliationDepartment of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa, Israel. rowe@jimmy.harvard.edulld:pubmed
pubmed-article:20629023pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20629023lld:pubmed